The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Treatments

Drug: Roflumilast

Study type

Interventional

Funder types

Industry

Identifiers

NCT00108823

BY217/M2-121

Details and patient eligibility

About

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

Written informed consent
Patients with a history of chronic obstructive pulmonary disease for at least 12 months as defined by the GOLD (Global Initiative on Obstructive Lung Diseases) criteria (2003)
Age ≥ 40 years
FEV1/FVC ratio (post-bronchodilator) ≤ 70%
FEV1 (post-bronchodilator) ≤ 65% of predicted
FRC (post-bronchodilator) ≤ 120% of predicted
Clinically stable COPD within 4 weeks prior to baseline visit (B0).
Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit (B0) or a willingness to have a chest x-ray performed at visit (B0).

Main Exclusion Criteria:

COPD exacerbation indicated by a treatment with systemic glucocorticosteroids not stopped at least 4 weeks prior to the baseline visit (B0)
Non smoker, current smoker or ex-smoker (smoking cessation at least one year ago) with a smoking history of < 10 pack years
Suffering from any concomitant disease that might interfere with study procedures or evaluation
Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit (B0)
Diagnosis of asthma and/or other relevant lung disease (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], and active tuberculosis)
Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 2 months preceding the baseline visit (B0).
Known alpha-1-antitrypsin deficiency
Need for long term oxygen therapy defined as ≥ 15 hours/day
Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)
Known infection with HIV, active hepatitis and/or liver insufficiency
Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within 5 years prior to study start
Clinically significant cardiopulmonary abnormalities (diagnosed clinically or by x-ray/ECG) that are not related to COPD and that require further evaluation
Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial
The female patient is of childbearing potential and is not using and is not willing to continue to use a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless she is surgically sterilized/hysterectomized or post-menopausal > 1 year or any other criteria considered sufficiently reliable by the investigator in individual cases
Participation in another study (use of investigational product) within 30 days preceding the baseline visit (B0) or re-entry of patients already enrolled in this trial
Suspected inability or unwillingness to comply with study procedures
Alcohol or drug abuse
Inability to follow study procedures due to, for example, language problems or psychological disorders
Use of prohibited drugs
Suspected hypersensitivity to the study medication and/or contraindication to any ingredients of the study medication (roflumilast) or rescue medication